|
|
||||||
Journal of Clinical Oncology, Vol 24, No 9 (March 20), 2006: pp. 1383-1388 © 2006 American Society of Clinical Oncology. DOI: 10.1200/JCO.2005.03.4413 Elevated Incidence of Lung Cancer Among HIV-Infected Individuals
From the Johns Hopkins Hospital, Baltimore; and the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD Address reprint requests to Eric A. Engels, MD, MPH, Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, DHHS, 6120 Executive Blvd, EPS 8010, Rockville, MD 20892; e-mail: engelse{at}exchange.nih.gov PURPOSE: People with HIV infection in the United States frequently smoke tobacco. We sought to characterize lung cancer incidence among HIV-infected individuals, examine whether cancer risk was related to HIV-induced immunosuppression, and assess whether the high prevalence of smoking explained elevated risk. METHODS: We conducted a retrospective cohort study at an HIV specialty clinic in Baltimore, MD (1989-2003). Incident lung cancers were identified using hospital records. We used negative binomial regression to compare incidence across subgroups defined by demographics, use of highly active antiretroviral therapy (HAART), and HIV markers. Standardized incidence ratios (SIRs) compared incidence with an urban reference population (Detroit, MI). We adjusted SIRs for the effect of smoking, using smoking prevalences estimated from part of the cohort and the general population. 95% CIs and P values were two sided. RESULTS: Thirty-three lung cancers were observed among 5,238 HIV-infected patients (incidence: 170 per 100,000 person-years). Incidence increased with age (P < .0001), but did not differ by sex, race, or CD4 count. Incidence tended to increase with calendar year (P = .09) and HAART use (P = .10), and was inversely related to HIV viral load (P = .03), but these associations were attenuated with age adjustment. The SIR was 4.7 (95% CI, 3.2 to 6.5) versus the general population. Twenty-eight lung cancer patients (85%) and 69% of the cohort were smokers. After smoking adjustment, risk remained elevated (SIR, 2.5; 95% CI, 1.6 to 3.5). CONCLUSION: Lung cancer risk was substantially elevated in HIV-infected individuals. Incidence was unrelated to HIV-induced immunosuppression. Notably, incidence remained high after adjustment for smoking, suggesting the involvement of additional factors. This work was supported by National Institutes of Health Grants No. DA11602 and DA00432 (R.D.M.), the National Cancer Institute's Specialized Program of Research Excellence Grant No. CA58184 (M.V.B.), and the Intramural Research Program of the National Cancer Institute (R.D.M.), Bethesda, MD. Presented in part at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article. This article has been cited by other articles:
|
||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|